| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
3.69(M) |
| Last
Volume: |
900 |
Avg
Vol: |
59,812 |
| 52
Week Range: |
$0.06 - $0.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Micati Victor P |
Director |
– • – |
2010-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
50,625 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2010-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,173 |
55,320 |
|
- |
|
| Mulligan Richard |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
17,475 |
|
- |
|
| Denner Alexander J |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,086 |
24,518 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
113,346 |
|
- |
|
| Salisbury Robert C |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
46,483 |
|
- |
|
| Micati Victor P |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
47,452 |
|
- |
|
| Young Richard A |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
14,180 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
52,147 |
|
- |
|
| Deuel Thomas |
Director |
– • – |
2010-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,043 |
14,180 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-06-18 |
4 |
S |
$11.25 |
$1,385,220 |
D/D |
(123,100) |
160,480 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2010-06-18 |
4 |
OE |
$8.59 |
$1,209,472 |
D/D |
140,800 |
283,580 |
|
- |
|
| Young Richard A |
Director |
– • – |
2010-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,137 |
7,137 |
|
- |
|
| Deuel Thomas |
Director |
– • – |
2010-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,137 |
7,137 |
|
- |
|
| Tooman Craig A |
Exec. V.P. Finance, CFO |
• – – |
2010-04-03 |
4 |
D |
$10.48 |
$62,146 |
D/D |
(5,930) |
138,906 |
|
- |
|
| Tooman Craig A |
Exec. V.P. Finance, CFO |
• – – |
2010-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,740 |
144,836 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-04-03 |
4 |
D |
$10.48 |
$29,616 |
D/D |
(2,826) |
90,509 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2010-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,570 |
93,335 |
|
- |
|
| Delcampo Ralph |
Chief Operating Officer |
• – – |
2010-04-03 |
4 |
D |
$10.48 |
$46,772 |
D/D |
(4,463) |
158,759 |
|
- |
|
| Delcampo Ralph |
Chief Operating Officer |
• – – |
2010-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,600 |
163,222 |
|
- |
|
| Horak Ivan D |
President of R&D |
• – – |
2010-04-03 |
4 |
D |
$10.48 |
$73,727 |
D/D |
(7,035) |
51,972 |
|
- |
|
| Horak Ivan D |
President of R&D |
• – – |
2010-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,860 |
59,007 |
|
- |
|
| Tooman Craig A |
Exec. VP Finance, CFO |
• – – |
2010-02-24 |
4 |
S |
$9.27 |
$1,390,635 |
D/D |
(150,000) |
128,096 |
|
- |
|
| Tooman Craig A |
Exec. VP Finance, CFO |
• – – |
2010-02-24 |
4 |
OE |
$5.73 |
$982,500 |
D/D |
150,000 |
278,096 |
|
- |
|
| Horak Ivan D |
EVP, R&D, CSO |
• – – |
2010-02-22 |
4 |
S |
$9.30 |
$942,578 |
D/D |
(101,329) |
39,147 |
|
- |
|
394 Records found
|
|
Page 8 of 16 |
|
|
